Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 17.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 219,568 shares of the biopharmaceutical company's stock after selling 47,311 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.45% of Theravance Biopharma worth $2,066,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in TBPH. Barclays PLC increased its position in Theravance Biopharma by 279.9% during the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company's stock worth $529,000 after purchasing an additional 48,316 shares in the last quarter. Magnetar Financial LLC grew its stake in shares of Theravance Biopharma by 125.8% in the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock worth $259,000 after purchasing an additional 15,328 shares in the last quarter. Teacher Retirement System of Texas bought a new position in Theravance Biopharma during the 4th quarter valued at $103,000. American Century Companies Inc. boosted its holdings in Theravance Biopharma by 11.9% during the fourth quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock worth $733,000 after buying an additional 8,289 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Theravance Biopharma during the fourth quarter valued at $69,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and a consensus price target of $11.33.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 6.90% of the company's stock.

Theravance Biopharma Stock Performance

TBPH stock traded down $0.09 during midday trading on Tuesday, reaching $9.67. 124,194 shares of the company's stock traded hands, compared to its average volume of 228,607. Theravance Biopharma, Inc. has a 52 week low of $7.44 and a 52 week high of $10.90. The firm has a market capitalization of $483.26 million, a PE ratio of -9.57 and a beta of 0.14. The company has a 50-day moving average price of $9.10 and a two-hundred day moving average price of $9.22.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). The business had revenue of $18.75 million for the quarter, compared to analysts' expectations of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.